The dose-response, double-blind, placebo-controlled, clinical study was published inSleep Medicine.120 physically healthy adults aged 18-70 years with self-reported poor sleep lasting longer than four weeks received either a placebo or different doses of affron one hour before going to bed, for 28 days.
The study showed that, compared to placebo, affron supplementation was associated with greater improvements in the primary outcome measures of sleep quality ratings, mood ratings after awakening, the ISQ total score, and ISQ-insomnia classifications. It was shown to be effective with a 14mg dose.
Related: Saffron Linked With Improvements in Menopausal Symptoms Private Equity Group Acquires Stake in Pharmactive Mental Health: The Next Crisis
Previous studies, the press release states, have found that affron affects the balance of neurotransmitters and offers antioxidant and anti-inflammatory properties. This study, additionally, showed increased levels of melatonin in the participants taking affron.Supplementation was well-tolerated with no reported significant adverse effects or sluggishness.
